Janssen Tabs Start-Up Scholar Rock For New Immunology Approach
This article was originally published in The Pink Sheet Daily
The J&J subsidiary has signed a deal with Boston-area Scholar Rock to discover new biologics that aim for a more pinpoint solution to inflammatory disease.
You may also be interested in...
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.
Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila’s lead compound as well as other compounds to emerge from its technology platform.